etivelcabtagene erigedleucel (UCART20x22) / Cellectis - LARVOL DELTA

ALEMTUZUMAB EXPOSURE AND SUSTAINED IL-2 DRIVE UCART20X22 EXPANSION AND CLINICAL RESPONSE INADULTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: NATHALI-01 STUDY (EHA 2026) - P1/2 | "Fludarabine, cyclophosphamide, and alemtuzumab (FCA) was investigated as the LD regimen. This observation supports the need to optimize LD and we are also currently investigating the use of subcutaneous low dose IL-2 to further enhance treatment response [NCT05607420]. Weight-based alemtuzumab might optimize trade-off between adequate exposure and toxicity mitigation."

Clinical • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • High-grade B-cell lymphoma • Immunology • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD22 • CD4 • CD52 • CXCL8 • IL2 • IL6

NATHALI-01 clinical trial evaluating eti-cel in r/r B-NHL - Poster Presentation (GlobeNewswire) - "As of the February 2026 data cutoff, 14 patients with r/r B-NHL had been treated across three dose levels...In the optimal dose cohort, ORR and complete response (CR) were 88% and 63%, respectively. The analysis identified a positive correlation between alemtuzumab exposure and clinical outcomes: higher alemtuzumab exposure created a favorable lower inflammatory homeostatic milieu prior to eti-cel infusion and was associated with enhanced eti-cel expansion and higher response rates. Additionally, responders maintained sustained low-level interleukin 2 (IL-2) secretion when compared to non-responders....The NATHALI-01 study is open for recruitment with the full Phase 1 clinical data expected in Q4 2026."

P1 data • B Cell Non-Hodgkin Lymphoma

Eti-cel – Poster Presentation (GlobeNewswire) - "The abstract from the Phase 1 NATHALI-01 study evaluating eti-cel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) has been accepted for poster presentation....The Phase 1 clinical data of the NATHALI-01 clinical trial are planned to be disclosed in Q4 2026."

P1 data • B Cell Non-Hodgkin Lymphoma

Lasme-cel – Oral Presentation (GlobeNewswire) - "The abstract reporting the full Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T, in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (r/r B-ALL), has been selected for oral presentation....The BALLI-01 trial is currently recruiting in Pivotal Phase 2 with interim data expected to be disclosed in Q4 2026."

P1 data • P2 data • B Acute Lymphoblastic Leukemia

Exogenous IL-2 administration promotes circulating T-cell levels, persistence and therapeutic efficacy of allogeneic UCART20x22 in a B-cell lymphoma mouse model (AACR 2026) - "The results of the in vivo studies support the use of IL-2 to improve the therapeutic outcomes of UCART20x22 in terms of depth and durability of disease response. This is currently being investigated in the NatHaLi-01 clinical study for R/R B-cell lymphomas, aiming to optimize response rates and durability of response in this patient population."

Preclinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • IL2

Weight based dosing of alemtuzumab as part of an enhanced lymphodepletion regimen may mitigate the risks of over and underexposure and improve response rates : Analysis of the nathali-01 trial (ASH 2025) - "LD regimens with alemtuzumab are currently being investigated in multiple clinical studies including the NatHaLi-01 study, a first-in-human, open-label, dose-finding and dose-expansion study of the dual CAR-T therapy UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). Adequate alemtuzumab exposure is important in achieving adequate lymphodepletion and disease response due to the positive impact on CAR-T cell expansion and the delay in host immune reconstitution. Increased weight with resultant lower alemtuzumab exposure may be associated with early host immune reconstitution and limited CAR T-cell expansion and suboptimal response. However, while adequate exposure is important, overexposure may be also associated with unnecessary toxicities which alters the risk benefit assessment."

B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01 (ASH 2025) - P1/2 | "After Lymphodepletion with FCA3 (fludarabine 30 mg/m2 × 3d,cyclophosphamide 0.5g/m2 × 3d, CLLS52 in a weight-based dose x 3 or 4d), a single infusion ofUCART20x22 is administered at a flat dose level ([DL1] 50 x 106 cells; [DL2] and 150 x 106 cells). Primary endpoints are incidence of dose-limiting toxicities andthe incidence and severity of treatment-emergent adverse events. Secondary endpoints includealemtuzumab PK parameters, objective response rate, duration of response, progression-free survival,and overall survival."

Clinical • IO biomarker • B Cell Non-Hodgkin Lymphoma • CNS Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • CD22

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) (ASH 2023) - P1/2 | "TALEN® gene editing technology is used to inactivate the TRAC and CD52 genes to minimize graft-versus-host disease (GvHD) and allow for the use of alemtuzumab (CLLS52, an anti-CD52 monoclonal antibody) in the lymphodepletion (LD) regimen, respectively...After LD with FCA (fludarabine 30 mg/m2 × 3d, cyclophosphamide 0.5g/m2 × 3d, CLLS52 12 mg on D1, 24 mg on D2, D3), a single infusion of UCART20x22 is administered at a flat dose level ([DL1] 50 x 106 cells; [DL2] 150 x 106 cells; and [DL3] 450 x 106 cells)...Pt 3 is an 18yo female with R/R DLBCL transformed from marginal zone lymphoma who previously received chemoimmunotherapy, venetoclax, ibrutinib, BR, CAR19, obinutuzumab, glofitamab, tafasitamab, lenalidomide, and an experimental epigenetic modifier...Pt 1 had G1 CRS and received tocilizumab (toci) x3 and dexamethasone (dex) x1... As of 01 July 2023, 3 pts were enrolled and treated at DL1. Pt 1 is a 76yo female with double-expressor diffuse large..."

CAR T-Cell Therapy • First-in-human • IO biomarker • P1/2 data • Aplastic Anemia • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD22 • CD8 • IFNG • IL2 • IL6 • TNFA

First poster – Development update on eti-cel (GlobeNewswire) - "Cellectis unveiled preliminary results on eti-cel, which demonstrate an encouraging overall response rate (ORR) of 86% and a complete response (CR) rate of 57% at the current dose level (n=7), with 4 out of 7 patients achieving a complete response. The preliminary high rate of complete responses underscores the potential of this innovative approach to transform outcomes for r/r NHL patients. Cellectis expects to present the full Phase 1 dataset for eti-cel, including low-dose IL-2 combination cohorts, in 2026."

P1 data • Non-Hodgkin’s Lymphoma

NatHaLi-01: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Cellectis S.A. | Trial completion date: Nov 2027 ➔ Aug 2027 | Trial primary completion date: Nov 2027 ➔ Aug 2027

Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • BCL6 • CD22

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates (GlobeNewswire) - "Pipeline Highlights:...NatHaLi-01 study evaluating eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL): Cellectis continues to focus on the enrollment of patients in the NatHaLi-01 study and expects to present a Phase 1 readout for eti-cel in r/r NHL in late 2025."

P1 data • Non-Hodgkin’s Lymphoma

Pipeline Highlights (GlobeNewswire) - "Cellectis continues to focus on the enrollment of patients in the BALLI-01 study and expects to present the Phase 1 dataset and late-stage development strategy for lasme-cel in r/r B-ALL in the third quarter of 2025; Cellectis continues to focus on the enrollment of patients in the NATHALI-01 study and expects to present a Phase 1 readout for eti-cel in r/r NHL in late 2025."

P1 data • B Acute Lymphoblastic Leukemia • Non-Hodgkin’s Lymphoma

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire) - "Pipeline Highlights:...(i) BALLI-01 study evaluating UCART22 in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL):...Cellectis continues to focus on the enrollment of patients in the BALLI-01 study and expects to present the Phase 1 dataset and late-stage development strategy for UCART22 in relapsed or refractory ALL in the third quarter of 2025; (ii) NATHALI-01 study evaluating UCART20x22 in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL): Cellectis continues to focus on the enrollment of patients in the NATHALI-01 study and expects to present the Phase 1 dataset and late-stage development strategy for UCART20x22 in relapsed or refractory NHL in late 2025."

Enrollment status • P1 data • Pipeline update • Acute Lymphocytic Leukemia • Non-Hodgkin’s Lymphoma

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) - "Cellectis...today announced that it has drawn down the final tranche of €5 million ('Tranche C') under the credit facility agreement for up to €40 million entered into with the European Investment Bank...With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22."

Financing • Oncology

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire) - "Cellectis continues to focus on the enrollment of patients in the BALLI-01 study, evaluating UCART22 in relapsed or refractory B-cell acute lymphoblastic leukemia. We expect to present the Phase 1 dataset and late-stage development strategy in 2025; Cellectis continues to focus on the enrollment of patients in the NATHALI-01 study, evaluating UCART20x22 in relapsed or refractory B-cell non-Hodgkin lymphoma. We expect to present the Phase 1 dataset and late-stage development strategy in 2025; The Company decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123, currently evaluated in relapsed or refractory acute myeloid leukemia."

Pipeline update • Trial status • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire) - "UCART Clinical Programs: Cellectis continues to focus on the enrollment of patients in the BALLI-01 study (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)...[and] in the NATHALI-01 study (evaluating UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)....We expect to provide updates in the advancements of BALLI-01 and NATHALI-01 by year-end 2024."

Enrollment status • P1/2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Non-Hodgkin’s Lymphoma

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) - "The Company plans to use the proceeds of Tranche B towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, and UCART123."

Financing • Hematological Malignancies • Oncology

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting (GlobeNewswire) - P1/2 | N=80 | NatHaLi-01 (NCT05607420) | Sponsor: Cellectis S.A. | "Cellectis...announced today that preliminary results of the Phase I NATHALI-01 clinical trial evaluating UCART20x22 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL)...will be presented at the American Society of Hematology 65th Annual Meeting (ASH 2023)....The poster presentation highlights the following data: as of July 1, 2023, 3 patients were enrolled and treated at dose level 1 (50 million cells) with product manufactured in-house by Cellectis. Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment....All patients responded at Day 28, with 1 partial metabolic response and 2 complete metabolic responses in patients who had failed prior autologous CD19 CAR T-cell therapies."

P1 data • Non-Hodgkin’s Lymphoma

NATHALI-01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC DUAL CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (NHL) (ICML 2023) - P1/2 | "After lymphodepletion with FCA (fludarabine 30 mg/m2 × 3d, cyclophosphamide 0.5g/m2 × 3d, alemtuzumab 12 mg on D1, 24 mg on D2, D3), patients will receive a single infusion of UCART20x22 at a flat dose level ([DL]; DL1-50 × 106 cells, DL2-150 × 106 cells, and DL3-450x106 cells). The trial is currently open for enrollment."

CAR T-Cell Therapy • Clinical • P1/2 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • IFNG

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire) - "The oral presentation highlighted the following preclinical data: Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations; Efficient in vitro targeting of primary B-cell Non-Hodgkin Lymphoma (B-NHL) samples harboring different CD20 and CD22 expression levels, suggesting that UCART20x22 has the potential to reach a large patient population; Dose dependent tumor control in vivo, using batches manufactured internally, harboring a tumor cell line as well as in a Patient Derived Xenograft (PDX) model of B-NHL."

Preclinical • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire) - "Cellectis...publishes an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, Cellectis’ first allogeneic dual CAR T-cell targeting the CD20 and CD22 antigens, to overcome current mechanisms of resistance to CAR T-cell therapies in B-cell Non-Hodgkin lymphoma (B-NHL), while providing a potential alternative to CD19 directed therapy."

Preclinical • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab (GlobeNewswire) - "Cellectis...announced it has implemented the use of alemtuzumab as a Cellectis Investigational Medicinal Product (IMP), coded as CLLS52, as part of the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory B-cell ALL, for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, and for UCART20x22 in the NatHaLi-01 clinical trial in relapsed/refractory B-cell NHL....Under the agreements, Sanofi is supplying alemtuzumab to support Cellectis’ clinical trials and the parties agreed to enter into discussions to execute a commercial supply of alemtuzumab under pre-agreed financial conditions."

Clinical protocol • Commercial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million (GlobeNewswire) - "The Company plans to use the proceeds of Tranche A towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1."

Commercial • Oncology

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares (GlobeNewswire) - "The Company plans to use (i) approximately $17.0 million (€15.6 million) of the net proceeds of the Global Offering to fund the continued clinical development of UCART 123, UCART22, UCART20x22, and UCARTCS1, and (ii) any remainder for working capital and other general corporate purposes."

Commercial • Oncology

Cellectis Announces Pricing of Follow-On Offering (Cellectis Press Release) - "Cellectis plans to use (i) approximately $17.0 million (€15.6 million) of the net proceeds of the Global Offering to fund the continued clinical development of UCART 123, UCART22, UCART20x22, and UCARTCS1, and (ii) any remainder for working capital and other general corporate purposes."

Commercial • Oncology